logo
Start intervention early to curb SVA, say experts

Start intervention early to curb SVA, say experts

The Star6 days ago
PETALING JAYA: Driven by dopamine-triggering features, the habit of endlessly scrolling through short videos is becoming a worrying trend in Malaysia – not just among adults, but increasingly among children too, say experts.
Consultant paediatrician and child disability activist Datuk Dr Amar Singh HSS said short video addiction (SVA) is now a global issue, and Malaysia is no exception.
ALSO READ: When habit takes a toll on real life
'Social media platforms like TikTok are attracting many young adults in Malaysia. Local studies have shown signs of TikTok addiction among youth,' he said when contacted.
One reason, he explained, lies in how these platforms are designed.
'They use algorithms that prio­ri­tise engagement, which often amplifies negative or sensational content. This kind of content is more attention-grabbing, which helps generate views and platform monetisation,' he said.
Supporting this, a study by Hong Kong-based Digital Business Lab showed TikTok's explosive growth in Malaysia.
ALSO READ: Hooked on autoplay, infinite scrolling and dopamine hits
In the first half of 2024 alone, the platform recorded 81.7 million downloads, a 6.6% increase from the previous year.
ByteDance's advertising data also reported 28.68 million TikTok users aged 18 and above in Malay­sia, equivalent to 84.4% of total internet users.
'As of January 2024, TikTok is the most popular social media platform, with 21.9% of users saying they love its engaging short-form videos,' the report stated.
Child expert Syaza Soraya Sauli of Universiti Teknologi Malaysia stressed the importance of early intervention, beginning at home and in pre-schools.
'More parents are giving gad­gets to their children, especially phones. This leads to what's now being called 'virtual autism',' she said, referring to children who exhibit autism-like behaviours due to prolonged screen exposure and limited social interaction.
'Many children aged below seven are already showing signs such as short attention spans, avoidance of physical activities and limited soft skills.
'They complain about hand pain when writing, give up on colouring quickly, yet can sit through hours of short videos.'
These children often lack gross motor skills such as coordination and strength, she added.
When assessed, Syaza said they appear 'autistic', but the root issue is screen overexposure, not neurodevelopmental disorders.
'Our current education system doesn't help. There's only one teacher per 25 students and natio­nal policy only mandates 20 minutes of structured free-play in pre-schools daily – far too little to build physical skills.'
Syaza said addressing SVA requires cooperation between parents and schools.
'Parents must reduce their own screen time alongside their children's, gradually. It's not easy because children may become emotionally distressed when gad­gets are taken away,' she said, recommending alternative outlets like outdoor play to release energy and emotions.
'While parents do their part at home, education policymakers must also ensure balance in the school curriculum by combining digital literacy with physical, hands-on learning. There should be more experiential learning,' she added.
'Balance is key to preventing SVA from becoming a major problem, as seen in Singapore and China,' said Syaza, who is currently pursuing her PhD in educational psychology.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UN agency: Almost a third of Gazans 'not eating for days'
UN agency: Almost a third of Gazans 'not eating for days'

New Straits Times

time3 hours ago

  • New Straits Times

UN agency: Almost a third of Gazans 'not eating for days'

ROME: Almost a third of people in Gaza are "not eating for days", the United Nations food aid agency told AFP on Friday, saying the crisis has reached "new and astonishing levels of desperation." The Rome-based World Food Programme had previously warned of a "critical risk of famine" in war-ravaged Gaza, over which international condemnation of Israel's actions has been growing. "Nearly one person in three is not eating for days. Malnutrition is surging with 90,000 women and children in urgent need of treatment," a WFP statement said. It said that 470,000 people are expected to face "catastrophic hunger" – the most critical category under the UN's Integrated Food Security Phase classification – between May and September this year. "Food aid is the only way for people to access any food as food prices are through the roof," the WFP said. "People are dying from lack of humanitarian assistance." Aid groups have warned of surging numbers of malnourished children in Gaza, which Israel placed under an aid blockade in March amid its war with Hamas.

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Malaysian Reserve

time13 hours ago

  • Malaysian Reserve

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)

Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation

Malay Mail

time17 hours ago

  • Malay Mail

Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation

HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: "MicroPort") announced that Shanghai Healthcare M&A Fund ("SHMAF"), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store